Considerations for Commonly Prescribed Medications by Dermatologists in Patients on Immune Checkpoint Inhibitors.

Abstract

Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many cancers. It is important for all members of the multidisciplinary teams supporting cancer patients to understand the impact of their clinical practice on immunotherapy response. Multiple medications have been implicated in altered ICI efficacy, of which many are first line treatments for common dermatologic conditions, including those arising as immune-related adverse events (irAEs). Cognizance of potential consequences associated with typical management strategies must be accounted for in this unique population. In this review, we hope to raise awareness of the potential impact that medications commonly prescribed by dermatologists may have on immunotherapy response. Specifically, we review the available evidence regarding the impact of antibiotics, systemic corticosteroids, Janus kinase inhibitors, biologics, and other immunomodulators. Improved understanding of these medication interactions will uphold informed management strategies for irAEs and coincidental dermatologic disorders in patients receiving ICIs, ultimately optimizing outcomes.